LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC

oncodaily - LIBRETTO-432 Trial was presented during ASCO 2026 by Jonathan W. Goldman, MD, as a global, multicenter, phase 3, double-blind, randomized, placebo-controlled study evaluating adjuvant selpercatinib in patients with early-stage RET […]

AI Summary: At ASCO26 plenary, LIBRETTO‑432 data show adjuvant selpercatinib markedly prolongs event‑free survival and slashes recurrence risk for patients with stage II–IIIA RET fusion–positive non‑small cell lung cancer after curative treatment. The findings support a new standard for this rare genetic subgroup and press the case for routine genomic testing.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 22 days

Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 3 days

DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 2 days

CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 16 days

Zanidatamab improves PFS over trastuzumab in HER2 GEA / 26 hrs

MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 28 hrs

Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 3 days